Bret Jensen

|RSS

Currently the editor of "The Biotech Forum," Bret Jensen was chief investment strategist for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami, from 2008-2011. The fund was in the top 5% of long/short hedge funds for total return in its first full year (2009), as ranked by Hedgeco fund database (more than 450 funds in category). Prior to this, he spent a decade as technology director of a Fortune 100 firm.Expand

Jensen has been a top-5%-ranked financial analyst and blogger since 2013, according to TipRanks. He holds a Bachelor of Science degree in finance from Arizona State University.

Follow Bret on Twitter: @Bret_Jensen.Collapse

RMPIA
By

Bret Jensen

 | Feb 8, 2017 | 8:57 AM EST
I had some technical difficulties getting online early today to participate in the Diary's conversation, but that has been resolved. I apologize for…
RMPIA
By

Bret Jensen

 | Feb 8, 2017 | 7:04 AM EST
I'm glad to be sitting in for Doug Kass on the Daily Diary over the next two days. There is plenty to talk about. Because we are the heart of earnings…
By

Bret Jensen

 | Feb 6, 2017 | 1:03 PM EST
Market down slightly across the board to start the trading week.  Added a few shares to two small cap concerns, that have been oversold on news...
By

Bret Jensen

 | Feb 3, 2017 | 1:14 PM EST
Market having big day across the board on robust economic readings late in week  We had a blowout ADP Jobs Report this Wednesday that easily...
By

Bret Jensen

 | Feb 3, 2017 | 1:00 PM EST
Both pharma companies are promising names that easily could become buyout targets.
RMPIA
By

Bret Jensen

 | Feb 1, 2017 | 11:30 AM EST
Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.
By

Bret Jensen

 | Feb 1, 2017 | 10:12 AM EST
Market is up across the board as the ADP Jobs Report shows a climb of just under 250,000 jobs for January.  This is big uptick from December and...
By

Bret Jensen

 | Jan 30, 2017 | 12:33 PM EST
Market going through its first "Trump hiccup", and probably not the last as botched & limited immigration ban rollout combined with overreaction...
RMPIA
By

Bret Jensen

 | Jan 30, 2017 | 10:00 AM EST
M&A, drug approvals and Trump are all on my watch list.
By

Bret Jensen

 | Jan 29, 2017 | 2:00 PM EST
The Actelion buyout opens the way for other deals.

BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.